Blog

Positive Data at American Thoracic Society International Conference

Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference

Preparations Underway for Launch of Multinational Phase 2 Study

DURHAM, N.C., May 24, 2017 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address Continue reading Positive Data at American Thoracic Society International Conference

CF Podcast 173: Becoming a Parent and Overcoming Infertility with Cystic Fibrosis

In this podcast, we meet Chris Kvam, cystic fibrosis patient, husband, and father. Diagnosed at 4 years old, Chris was told he was infertile, very abruptly, when switching over to his adult cystic fibrosis clinic. Because of the delivery and lack of open conversation about the topic, to this day, he feels that the news was the Continue reading CF Podcast 173: Becoming a Parent and Overcoming Infertility with Cystic Fibrosis

New Drug to Help with Resistant Fungal Lung Infections

TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections. Continue reading New Drug to Help with Resistant Fungal Lung Infections

Spyryx Biosciences Partners with Cystic Fibrosis Canada, Serves as Presenting Sponsor of the 16th Broken Arrow Conference May 4-6, Toronto, Ontario

Company continues its outreach to the CF community in support of SPX-101’s Phase 2 clinical program

DURHAM, N.C., May 4, 2017 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung disease, announced today that it will serve as the presenting sponsor Continue reading Spyryx Biosciences Partners with Cystic Fibrosis Canada, Serves as Presenting Sponsor of the 16th Broken Arrow Conference May 4-6, Toronto, Ontario

Scientists turn human induced pluripotent stem cells into lung cells: ‘Bronchospheres’ may pave way for personalized cystic fibrosis treatments — ScienceDaily

https://www.sciencedaily.com/releases/2017/05/170503131922.htm

For years, scientists who study lung diseases like cystic fibrosis have tried to track this process in detail, from start to finish, in the hope that understanding how lungs form normally may help explain how things go wrong. Now, scientists at Boston University’s Center for Regenerative Medicine (CReM) have announced Continue reading Scientists turn human induced pluripotent stem cells into lung cells: ‘Bronchospheres’ may pave way for personalized cystic fibrosis treatments — ScienceDaily

Vertex Grants $1 Million to Non-Profits for Cystic Fibrosis

http://www.raredr.com/

Earlier today, Vertex Pharmaceuticals Incorporated – a corporation designed to fund scientific innovation to create transformative medicines for people with serious and life-threatening diseases – announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program. Continue reading Vertex Grants $1 Million to Non-Profits for Cystic Fibrosis

Podcast 172: Exercising While in the Hospital

In this podcast, Jerry Cahill reviews several ways that he stays active in the hospital in order to keep his lungs clear and discusses the importance of holding on to your routine.
https://www.youtube.com/watch?v=QEY7y3-rF40&feature=youtu.be

This video podcast was made possible through an unrestricted education grant from Gilead to the Boomer Esiason Foundation.

Subject: CF MiniCon: Transplant – May 21 Virtual Event for Adults With CF

This year the Cystic Fibrosis Foundation will be supporting three virtual events created by and for adults with CF to connect and share their experiences. In 2016, a group of adults with CF created BreatheCon, a two-day event that had a powerful effect in connecting community members. This year, in addition to BreatheCon, we are also introducing two CF MiniCons, which are one-day, topic-specific virtual events.

While last year’s BreatheCon was a pilot program, with 188 attendees and limited mostly to word of mouth promotion, this year we encourage you to spread the word about these virtual events to all adults with CF. Please note these events are open only to adults with CF (not to Care Center staff).

CF MiniCon: Transplant – May 21

On Sunday, May 21 from 6:00 – 9:30 p.m. Eastern Time, members of the CF community will be hosting CF MiniCon: Transplant, where adults with CF can have an honest and open dialogue about the transplant process.

This virtual event will include presentations, group chats, and small group video breakouts on a variety of aspects of transplantation that are unique to people living with CF. Discussion will focus on lifestyle, not on medical topics.

All adults with CF age 18 and over are welcome to attend CF MiniCon: Transplant. Registration is open now through May 18 at www.cff.org/minicon. For questions or more information, email  breathecon@cff.org.

Additional 2017 Events
Please be on the lookout for additional details on CF MiniCon: Young Adult Transition (July 22) and BreatheCon 2017 (September 8-9) in the weeks leading up to the events. If you would like to recommend someone from your community who has CF and is age 18 or over to help plan these events, or if you have any questions, please email Danielle Lowe Cipriani at dcipriani@cff.org.

We look forward to working with you to support virtual connections for people living with CF.

Thank you,
Drucy Borowitz, M.D.

Vice President of Community Partnerships

GlaxoSmithKline recalls nearly 600,000 albuterol inhalers

https://www.mdlinx.com/pharmacy/medical-news-article/2017/04/17/7131165/?news_id=980&newsdt=041717&subspec_id=587&utm_source=DailyNL&utm_medium=newsletter&utm_content=General-Article&utm_campaign=article-section&category=latest&page_id=1

The three affected lot numbers are 6ZP9848, 6ZP0003, and 6ZP9944. GlaxoSmithKline is voluntarily recalling 593,088 Ventolin HFA 200D albuterol Continue reading GlaxoSmithKline recalls nearly 600,000 albuterol inhalers

USACFA Scholarship Opens June 1st 2017-June30th for Fall 2017!

Please share with young adults who would be interested and qualified!

The United States Adult Cystic Fibrosis Association (USACFA) is excited to offer the Lauren Melissa Kelly Scholarship award for the Fall semester 2017. The scholarship will range from $1500 to $2500 and be awarded to adults with cystic fibrosis who are pursuing career certifications, associates, and bachelor’s degrees.

Continue reading USACFA Scholarship Opens June 1st 2017-June30th for Fall 2017!